Ahead of the Curve


Orna Therapeutics is leaving linear thinking behind to create fully engineered oRNATM circular RNAs – an entirely new class of RNA medicines that can realize the full potential of RNA and which is poised to change the way we treat disease.


RNA has recently ascended as a therapeutic class with vast potential. Existing mRNA technologies, however, face numerous and ongoing challenges to production, delivery, and performance. Circular RNA, by its very nature, has the potential to address these challenges, but the technology to create and engineer these molecules efficiently in a laboratory setting remained undeveloped. Orna now has this technology – building on nature’s ingenuity with our sophisticated molecular innovations to advance a system for protein expression, RNA production, and superior delivery compared to conventional long RNA approaches. We have married these capabilities with exciting delivery solutions to create a simple, powerful platform: the next breakthrough in RNA therapeutics.

Our Team

Creating a new class of therapeutics requires thinking outside the lines. Comprised of a team of skilled scientists, molecular engineers, and industry veterans in addition to a world class Board, we are well-suited for the challenge of bringing the promise of our oRNATM therapeutics to patients.

Thomas Barnes, PhD
Chief Executive Officer
Amy Becker, PhD
Director, Immunology
Nelson Chau, PhD
Senior Vice President, Platform
Claudia Harper, DVM
Senior Vice President, Preclinical Safety
Daniel Anderson, PhD
Professor, Massachusetts Institute of Technology
Sakae Asanuma, CFA
President, Taiho Ventures
Thomas Barnes, PhD
CEO, Orna Therapeutics
Thomas Ebeling
Advisor, MPM Capital


mRNA-Based Therapeutics Summit Europe

January 25-27, 2022

9th International mRNA Health Conference

November 09-10, 2021

SVB Leerink Biopharma Private Company Connect

October 27-29, 2021